1. Home
  2. ALAR vs BLRX Comparison

ALAR vs BLRX Comparison

Compare ALAR & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alarum Technologies Ltd.

ALAR

Alarum Technologies Ltd.

N/A

Current Price

$1.22

Market Cap

10.7M

Sector

Technology

ML Signal

N/A

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

N/A

Current Price

$1.52

Market Cap

11.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALAR
BLRX
Founded
2013
2003
Country
Israel
Israel
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7M
11.7M
IPO Year
2018
2010

Fundamental Metrics

Financial Performance
Metric
ALAR
BLRX
Price
$1.22
$1.52
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$16.00
★ $22.00
AVG Volume (30 Days)
★ 30.6K
10.4K
Earning Date
11-25-2026
11-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$24.89
$37.33
Revenue Next Year
$26.13
$37.06
P/E Ratio
$44.31
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$1.60
52 Week High
$14.50
$3.95

Technical Indicators

Market Signals
Indicator
ALAR
BLRX
Relative Strength Index (RSI) 34.32 18.16
Support Level N/A N/A
Resistance Level $1.59 $3.04
Average True Range (ATR) 0.09 0.12
MACD -0.00 -0.03
Stochastic Oscillator 20.00 9.78

Price Performance

Historical Comparison
ALAR
BLRX

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: